Quantcast

Latest Rhinology Stories

2008-11-07 09:00:05

Morria Biopharmaceuticals, a developer of anti-inflammatory drugs, has announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The nasal allergen challenge study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared with both placebo (arm 1) and an intranasal steroid Rhinocort (as a positive control, arm 2)....

2008-11-06 11:17:34

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared...

2008-10-30 12:00:21

Morria Biopharmaceuticals, a developer of novel, anti-inflammatory drugs, has announced the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort as the steroid comparator arm. A secondary efficacy endpoint of this study was the effect of MRX-4 on inflammatory mediators or markers in the...

2008-10-29 12:00:07

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm. A secondary efficacy...

2008-10-28 06:00:28

Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation. Anders Lonner, CEO of Meda, said: "This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute...

2008-10-17 03:00:16

Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray. The active substance in these products is azelastine - the leading nasal antihistamine in the treatment of rhinitis in the U.S. Astepro is now approved for treatment of seasonal allergic rhinitis. Fewer reports...

2008-10-06 21:00:11

Thai researchers suggest patients on allergy medicine are better served when they adjust their dose to symptoms. The researchers found the effectiveness of intranasal corticosteroids -- a drug that reduces swelling and secretions in the nose -- could be achieved with three-quarters of the usually recommended daily dosage when patients were instructed how to vary the daily dosage in response to severity of symptoms. This new approach to dosing could help prevent the problem of increased...

2008-10-02 06:00:34

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous phase II clinical trial,...

2008-09-26 12:00:35

Breathe Again(TM), Europe's best selling hypertonic saline nasal spray, is now available in the United States. Clinically tested in France, Breathe Again (www.breatheagain.us) is 100% natural, combining the benefits of pure seawater and the drying effect of a hypertonic solution. Harvested from Europe's purest tidal seawater off the coast of Saint Malo, France, the superior and unique nasal spray can be used for allergy prevention, nasal congestion, sinus problems and nasal hygiene. With...

2008-09-24 12:00:37

Sanofi-Aventis has announced that the FDA has approved Nasacort AQ nasal spray for children aged two to five years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal symptoms of year-round allergies in children between two and five years. This is said...


Latest Rhinology Reference Libraries

Politzerization
2012-12-31 12:28:34

In 1861 Adam Politzer of Vienna spent much time studying the air movement in the Eustachian tubes and the ear canal. He would measure the air movement by attaching a manometer, a very large gauge, to the ear canal and the pharynx. He developed an apparatus known as the Politzer bag in 1863 which is a less invasive way to clear the Eustachian tubes. Procedure Politzerization, also known as the Politzer maneuver, is a medical procedure which inserts air in the middle ear while the patient...

More Articles (1 articles) »
Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.